Abstract:Introduction Ketamine, a versatile anesthetic, has seen increased recreational use, leading to significant health issues, including ketamine‐induced uropathy (KIU). KIU manifests with lower urinary tract symptoms (LUTS) and can involve the upper urinary tract. This study aims to provide a comprehensive overview of KIU, addressing its pathophysiology, diagnostic strategies, and treatment options; and to define/identify future research priorities. Methods During the 2024 meeting of the International Consultation on Incontinence Research Society (ICI‐RS) in Bristol, a dedicated Proposal (P) convened to explore KIU. This initiative involved a thorough review of existing literature, expert presentations, and consensus‐driven discussions. The methodology ensured a comprehensive exploration of KIU from both clinical and pre‐clinical perspectives, leading to actionable research recommendations. Results Understanding the mechanisms of KIU is crucial for developing effective treatment options targeting specific pathophysiological pathways. Key findings include bladder fibrosis driven by transforming growth factor‐β1 (TGF‐β1), elevated purinergic responses and upregulated P2X1 purinoceptor expression, decreased barrier function due to increased expression of antiproliferative factor (APF), and functional loss of the bladder through Cav1.2 channel blockade. Research indicates that fibrosis, typically considered irreversible, may be mitigated. However, the exact timing and extent of fibrosis initiation and its impact on long‐term outcomes require further research. LUTS typically improve after ketamine cessation but relapse upon resumption, indicating a hypersensitivity mechanism involving elevated serum IgE levels. Advanced stages of KIU do not always correlate with LUTS severity, shedding light on potential systemic effects and the need for evaluating liver enzymes. Furthermore, psychological dependency on ketamine, due to its positive perceptive and mood‐altering effects, complicates cessation efforts. Long‐term management requires a holistic approach, integrating medical treatments and supportive measures to help patients navigate life with potentially irreversible complications. Conclusion This comprehensive review spans from fundamental pathology to practical clinical management, addressing both urological and systemic complications, and bridging insights from animal models to human applications. Developing effective treatment strategies necessitates addressing both the physical and psychological aspects of ketamine dependency.

Clinical Staging of Ketamine-Associated Urinary Dysfunction: a Strategy for Assessment and Treatment

Advance research on ketamine associated lower urinary tract symptoms

Ketamine-Associated Urinary Tract Dysfunction: an Underrecognized Clinical Entity

Can We Better Understand, Diagnose, and Treat Ketamine‐Induced Uropathy, and Can It Be Reversed? ICI‐RS 2024

Ketamine-Induced Lower Urinary Tract Symptoms: A Study of International Prostate Symptom Score and Quality of Life

Lower Urinary Tract Destruction Due to Ketamine A Report of 4 Cases and Review of Literature

Newer therapies and surgical management of ketamine-induced uropathy: A review

Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment

Risk of Renal Function Decline in Patients with Ketamine-Associated Uropathy

Association of urinary ketamine and APOA1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses

Misdiagnosis analysis for street ketamine associated urinary system dysfunction

British Association of Urological Surgeons Consensus statements on the management of ketamine uropathy

Cognitive Impairment in Ketamine Dependent Subjects

The Therapeutic Effects of Cystectasia with Sodium Hyaluronate Solution on Ketamine Related Cystitis

Use of Staging Models for Treatment-Resistant Depression Is Not Helpful in Predicting Nonresponse to Acute Intravenous Ketamine Treatment

The Pharmacological Management of Ketamine Use Disorder: A Systematic Review

Meta-Analysis of the Efficacy and Safety of Ketamine on Postoperative Catheter-Related Bladder Discomfort

BDNF-ERK1/2 signaling pathway in ketamine-associated lower urinary tract symptoms

Artificial intelligence‐based drug repurposing with electronic health record clinical corroboration: A case for ketamine as a potential treatment for amphetamine‐type stimulant use disorder

Ketamine enhances autophagy and endoplasmic reticulum stress in rats and SV-HUC-1 cells via activating IRE1-TRAF2-ASK1-JNK pathway

Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute Ischemic Stroke in Chinese Patients